Table 2.
Immunophenotyping in patient 1: At the time of first presentation, the T and NK cells were particularly low, and the IL2 receptor expression was above the reference level. After 8 months of prednisone treatment, the T cell levels had slightly improved, but the B cells subsequently declined significantly. At 2 months after dose reduction, the T cells had minorly decreased again, whereas the Il2 receptor expression had increased.
| Initial | +8 months a | +14 months b | +16 months | +2 years | +4 years | Reference level | |
|---|---|---|---|---|---|---|---|
| Total leucocytes [/µl] | 6000.0 | 7500.0 | 7500.0 | 7300.0 | 5200.0 | 5600.0 | 4600–7100/µl |
| Lymphocytes abs [/µl] | 480.0 (↓) | 510.0 (↓) | 442.0 (↓) | 533.0 (↓) | 598.0 (↓) | 640.0 (↓) | 1600–2400/µl |
| Lymphocytes rel [%] | 8.0 (↓) | 6.8. (↓) | 5.9 (↓) | 7.3 (↓) | 11.5 (↓) | 11.5% (↓) | 28–39% |
| B lymph CD19+ abs [/µl] | 187.0 (↓) | 51.0 (↓) | 58.0 (↓) | 91.0 (↓) | 120.0 (↓) | 209 | 200–400/µl |
| B lymph CD19+ rel [%] | 39.0 | 10.0 (↓) | 13.0 | 17.0 (↑) | 20.0 (↑) | 26.1 (↑) | 11–16% |
| T lymph CD3+ abs [/µl] | 139.0 (↓) | 163.0 (↓) | 111.0 (↓) | 139.0 (↓) | 221.0 (↓) | 409.0 (↓) | 1100–1700/µl |
| T lymph CD3+ rel [%] | 29.0 (↓) | 32.0 (↓) | 25.0 (↓) | 26.0 (↓) | 37.0 (↓) | 51.3 (↓) | 67–76% |
| TH CD3+ CD4+ abs [/µl] | 106.0 (↓) | 112.0 (↓) | 80.0 (↓) | 107.0 (↓) | 173.0 (↓) | 331.0 (↓) | 700–1100/µl |
| Tsuppr CD3+CD8+ abs [/µl] | 29.0 (↓) | 46.0 (↓) | 35.0 (↓) | 43.0 (↓) | 54.0 (↓) | 58.0 (↓) | 500–900/µl |
| Quot CD4/CD8 | 3.7 (↑) | 2.4 (↑) | 2.3 (↑) | 2.5 (↑) | 3.2 (↑) | 5.7 (↑) | 1.0–1.5 |
| Quot CD11b-/11b+ CD8 | 0.8 | 0.4 | 0.2 | 0.3 | 0.6 | nd | <3 |
| Ttox CD11b-CD8+ [/µl] | 34.0 | 41.0 | 18.0 | 37.0 | 66.0 | nd | |
| T suppr CD11b+CD8+ [/µl] | 43.0 | 97.0 | 106.0 | 123.0 | 114.0 | nd | |
| NK CD57 CD8 [/µl] | 48.0 (↓) | 87.0 (↓) | 97.0 (↓) | 96.0 (↓) | 66.0 (↓) | nd | 100–360/µl |
| NK C16 CD56 [/µl] | 144.0 (↓) | 275.0 | 212 | 298.0 | 269.0 | nd | 200–400/µl |
| HLA DR expr T CD3+ [%] | 36.7 (↑) | 29.0 (↑) | 35.7 (↑) | 31.2 (↑) | 21.6 (↑) | nd | 8–15% |
| IL 2R expr CD25 CD3 [%] | 55.2 (↑) | 53.1 (↑) | 60.0 (↑) | 57.7 (↑) | 51.4 (↑) | nd | 13–24% |
After 8 months of treatment with prednisone, mefloquine, and mirtazapine.
At 2 months after dose reduction of prednisone.
Pathological values are bold. Arrows depict whether a value is above or below the reference level.
−, negative; +, positive; abs, absolute; expr, expression; HLA, human leucocyte antigen; IL2R, interleukin 2 receptor; lymph, lymphocytes; NK, natural killer; quot, quotient; rel, relative; TH, T helper cells; Tsuppr, T suppressor cells; Ttox, cytotoxic T cells.